S&P 500
7,757.17
+44.60
+0.58%
Dow
52,856.09
+360.19
+0.69%
Nasdaq
26,702.86
+278.04
+1.05%
NYSE Composite
24,253.12
+62.52
+0.26%
Russell 2000
2,781.02
+7.60
+0.27%
VIX
16.68
-0.63
-3.64%
MREO · Mereo BioPharma Group plc American Depositary Shares
NASDAQ NMS - GLOBAL MARKET - BOATS Real Time Price • USD
Mereo BioPharma Group PLC (MREO)
NASDAQ NMS - GLOBAL MARKET
Biotechnology
$0.29
-0.01
(-2.56%)
● At close: October 21 at 4:00:00 PM EDT
$0.26
-0.03
(-10.47%)
Overnight:
8:14:26 PM EDT
DAY'S RANGE
$0.29
$0.29
$0.31
52-WEEK RANGE
$0.29
$0.20
$2.37
What's happening
- MREO is down 2.56% today, trading at $0.29. — Live quote
- Volume today (2,900) is well below its 3-month average of 3,284,090. (Finnhub fundamentals)
- Reports earnings on 2026-11-09, 18 days away. (Finnhub earnings calendar)
- Last quarter's EPS missed estimates: $-0.01 actual vs. $-0.01 estimated (-22.0%). (Finnhub earnings history)
Deterministic template sentences filled in from the same sourced figures shown elsewhere on this page -- not an AI-written summary, no live model call.
Key Statistics
Analyst Recommendations
Strong buy 5
Buy 5
Hold 2
Sell 1
Strong sell 0
Aggregate ratings for 2026-10-01 (13 analysts polled by Finnhub) — consensus count.
Performance Overview (Trailing returns vs S&P 500 benchmark)
YTD RETURN
MREO
-29.18%
vs S&P 500
-41.96%
1-YEAR RETURN
MREO
-86.83%
vs S&P 500
-101.39%
6-MONTH RETURN
MREO
-9.56%
3-MONTH RETURN
MREO
-3.50%
Earnings Trends (Quarterly EPS Actual vs Estimate)
2026-07-26 (Q2 2026)
$-0.01
Est. $-0.01
MISS -22.0%
2026-04-26 (Q1 2026)
$-0.01
Est. $-0.01
BEAT +2.0%
2026-01-26 (Q4 2025)
$-0.01
Est. $-0.01
BEAT +23.7%
2025-10-26 (Q3 2025)
$-0.01
Est. $-0.02
BEAT +59.7%
Valuation Measures & Ratios
Enterprise Value4$18.1M
Forward P/E5—
PEG Ratio6—
Price / Sales (TTM1)96.44
Price / Book71.77
EV4 / Revenue—
EV4 / EBITDA—
Profit Margin—
Operating Margin—
Return on Equity (ROE8)-55.21%
Return on Assets (ROA9)-47.78%
Avg Volume (3M)3,284,090
Quarterly history (5 periods)
| Measure | Jun '26 | Mar '26 | Sep '25 | Jun '25 | Mar '25 |
|---|---|---|---|---|---|
| Market cap | $232.1M | $226.1M | $1.45B | $1.98B | $1.45B |
| P/E | -6.56 | -5.48 | -29.21 | -36.23 | -29.53 |
| Price/Book | 8.10 | 6.64 | 31.05 | 36.62 | 24.13 |
| ROE | -123.43% | -121.12% | -106.29% | -101.07% | -81.71% |
| ROA | -101.87% | -101.56% | -92.40% | -87.43% | -71.86% |
Trailing-twelve-month ratios computed from SEC EDGAR quarterly figures and historical daily close prices (Alpaca). Diluted shares are derived from Net income ÷ EPS (diluted) for each quarter, not separately reported. Forward P/E/PEG unavailable (no free data source).
Glossary — what these abbreviations mean
- 1. TTM
- Trailing twelve months — the sum of the last four reported quarters, not a calendar year or the single latest quarter.
- 2. EPS
- Earnings per share — net income divided by diluted shares outstanding.
- 3. Beta
- A stock's historical volatility relative to the overall market. Above 1 means it has moved more than the market; below 1, less.
- 4. EV (Enterprise Value)
- Market cap plus total debt minus cash — roughly what it would cost to buy the whole company, debt included.
- 5. Forward P/E
- Price divided by analysts' estimated earnings for the next 12 months, instead of trailing actual earnings.
- 6. PEG Ratio
- P/E divided by expected earnings growth rate. A lower number can indicate a stock is cheap relative to how fast it's expected to grow.
- 7. Price / Book
- Share price divided by book value (assets minus liabilities) per share.
- 8. ROE
- Return on equity — net income divided by shareholders' equity, a measure of how efficiently a company turns equity into profit.
- 9. ROA
- Return on assets — net income divided by total assets, a measure of how efficiently a company turns assets into profit.
- 10. MRQ
- Most recent quarter — the single latest reported period, as opposed to TTM. The Financials section's "Quarterly" view below shows MRQ-style figures.
- 11. YoY
- Year over year — percent change versus the same period one year earlier, used for growth figures like those on Compare cards and the Screener.
Short Interest
Shares Short2,678,406
Change from Prior Settlement-12.92%
% of Float—
Days to Cover (Short Ratio)1.25
Source: FINRA Rule 4560 consolidated short interest, settlement date 2026-09-30. Reported bi-monthly with a reporting lag — not real-time.
Quotes and the 1-day extended-hours chart: Yahoo Finance. Longer historical charts: Alpaca (IEX feed) — real-time but IEX-only volume (~2.5% of consolidated market volume). Fundamentals + earnings: Finnhub.
Price history
Events
Drag horizontally to zoom into a section; use Reset view to restore all observations.
Technical signal summary
Calculating from the latest year of daily price history…
Show Technical Analysis Breakdown ▾ 10 Indicators
Not investment advice — read several signals together.
Indicators None active
Loading chart…
History limited by data provider; markers are heuristics, not signals.
Peer and sector context
No reviewed peer group is available for this symbol.
Balanced evidence
A deterministic summary of sourced facts—not an AI verdict.
Potential strengths
- Latest SEC filing is Form 8-K, filed 2026-08-19; review it for current changes and risks. SEC EDGAR ↗
Potential concerns
- Trailing 52-week price return is -86.8%. Finnhub market metrics ↗
Rule-based facts only; absence from either side is not evidence, and this is not a recommendation.
More on MREO
No accessible free API for these — links go to the source directly.
Financials
Fundamental trends
Visualized from the same SEC figures in the tables below.
Income statement
| Line item | Jun '26 | Mar '26 | Sep '25 | Jun '25 | Mar '25 | Sep '24 | Jun '24 | Mar '24 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | — | $0 | $500.0K | — | $0 | $0 | $0 |
| Operating income | -$7.0M | -$8.8M | -$10.0M | -$10.5M | -$11.2M | -$9.4M | -$12.8M | -$9.9M |
| Net income | -$7.0M | -$6.7M | -$7.0M | -$14.6M | -$12.9M | -$15.0M | -$12.3M | -$9.0M |
| EPS (diluted) | $-0.01 | $-0.01 | $-0.01 | $-0.02 | $-0.02 | $-0.02 | $-0.02 | $-0.01 |
| EPS (basic) | $-0.01 | $-0.01 | $-0.01 | $-0.02 | $-0.02 | $-0.02 | $-0.02 | $-0.01 |
| Operating margin | — | — | — | -$2.1K | — | — | — | — |
| Net margin | — | — | — | -$2.9K | — | — | — | — |
Balance sheet
| Line item | Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 |
|---|---|---|---|---|---|---|---|---|
| Total assets | $34.7M | $40.6M | $45.9M | $53.6M | $62.6M | $68.3M | $76.4M | $88.7M |
| Total liabilities | $6.1M | $6.6M | $5.0M | $7.0M | $8.5M | $8.2M | $15.4M | $16.2M |
| Stockholders' equity | $28.7M | $34.1M | $40.9M | $46.6M | $54.2M | $60.1M | $61.0M | -$72.5M |
| Total current assets | $33.4M | $40.0M | $45.0M | $52.4M | $61.4M | $66.9M | $74.8M | $86.7M |
| Total current liabilities | $5.7M | $6.2M | $4.3M | $6.0M | $7.6M | $7.5M | $13.8M | $14.2M |
| Cash & equivalents | $30.1M | $30.1M | $41.0M | $48.7M | $56.1M | $62.5M | $69.8M | $80.5M |
| Property, plant & equipment | $54.0K | $91.0K | $137.0K | $174.0K | $218.0K | $247.0K | $257.0K | $315.0K |
| Intangible assets | $256.0K | $381.0K | $516.0K | $643.0K | $470.0K | $554.0K | $643.0K | $799.0K |
| Accounts payable | $1.1M | $3.2M | $1.3M | $879.0K | $1.1M | $2.9M | $2.4M | $1.7M |
| Accrued liabilities | $2.5M | $2.0M | $2.0M | $4.1M | $5.0M | $2.9M | $4.1M | $3.5M |
| Other current liabilities | $1.1M | $905.0K | $741.0K | $622.0K | $777.0K | $894.0K | $1.1M | $2.6M |
| Other non-current liabilities | $370.0K | $362.0K | $661.0K | $652.0K | $352.0K | $325.0K | $565.0K | $568.0K |
| Common stock & paid-in capital | $3.1M | $3.1M | $3.1M | $3.1M | $3.1M | $3.1M | $3.1M | $3.1M |
| Retained earnings | -$514.5M | -$507.5M | -$501.0M | -$493.7M | -$486.6M | -$472.0M | -$462.9M | -$455.8M |
| Accumulated other comprehensive income (loss) | -$12.3M | -$12.6M | -$10.8M | -$10.9M | -$8.6M | -$15.3M | -$18.8M | -$11.1M |
Cash flow
| Line item | Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 |
|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$6.0M | -$4.3M | -$7.7M | -$7.3M | -$7.7M | -$8.3M | -$9.4M | -$7.5M |
| Investing cash flow | $0 | -$300.0K | $0 | $300.0K | $0 | -$320.0K | $0 | $0 |
| Financing cash flow | $0 | $0 | $39.0K | $0 | -$134.0K | $422.0K | -$40.0K | -$594.0K |
| Free cash flow | -$6.0M | -$4.3M | -$7.7M | -$7.3M | -$7.7M | -$8.3M | -$9.4M | -$7.5M |
| Capital expenditures | $0 | $0 | $0 | $0 | $0 | $20.0K | $0 | $0 |
| Share-based compensation | $1.3M | $1.6M | $1.5M | $1.7M | $2.1M | $2.3M | $1.5M | $1.7M |
| Deferred income taxes | — | — | — | — | — | — | $0 | — |
| Change in accounts payable | -$2.1M | $2.0M | $447.0K | -$236.0K | -$2.0M | $362.0K | $843.0K | -$1.1M |
Income statement
| Line item | Dec '25 | Dec '24 | Dec '23 | Dec '22 |
|---|---|---|---|---|
| Revenue | $500.0K | $0 | $10.0M | $0 |
| Operating income | -$40.1M | -$47.4M | -$28.4M | -$54.4M |
| Net income | -$41.9M | -$43.3M | -$29.5M | -$42.2M |
| EPS (diluted) | $-0.05 | $-0.06 | $-0.04 | $-0.07 |
| EPS (basic) | $-0.05 | $-0.06 | $-0.04 | $-0.07 |
| Operating margin | -$8.0K | — | -$284 | — |
| Net margin | -$8.4K | — | -$295 | — |
Balance sheet
| Line item | Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 |
|---|---|---|---|---|---|
| Total assets | $45.9M | $76.4M | $66.5M | $77.4M | — |
| Total liabilities | $5.0M | $15.4M | $16.0M | $26.0M | — |
| Stockholders' equity | $40.9M | $61.0M | $50.5M | $51.4M | $92.2M |
| Total current assets | $45.0M | $74.8M | $63.8M | $75.2M | — |
| Total current liabilities | $4.3M | $13.8M | $9.5M | $24.4M | — |
| Cash & equivalents | $41.0M | $69.8M | $57.4M | $68.2M | — |
| Property, plant & equipment | $137.0K | $257.0K | $405.0K | $551.0K | — |
| Intangible assets | $516.0K | $643.0K | $1.1M | $0 | — |
| Accounts payable | $1.3M | $2.4M | $2.3M | $3.5M | — |
| Accrued liabilities | $2.0M | $4.1M | $5.5M | $5.4M | — |
| Other current liabilities | $741.0K | $1.1M | $1.0M | $1.1M | — |
| Other non-current liabilities | $661.0K | $565.0K | $764.0K | $0 | — |
| Common stock & paid-in capital | $3.1M | $3.1M | $2.8M | $2.5M | — |
| Retained earnings | -$501.0M | -$462.9M | -$419.6M | -$404.6M | — |
| Accumulated other comprehensive income (loss) | -$10.8M | -$18.8M | -$17.5M | -$21.7M | — |
Cash flow
| Line item | Dec '25 | Dec '24 | Dec '23 | Dec '22 |
|---|---|---|---|---|
| Operating cash flow | -$31.0M | -$32.8M | -$21.1M | -$48.8M |
| Investing cash flow | -$20.0K | -$699.0K | -$419.0K | $2.0M |
| Financing cash flow | $327.0K | $46.1M | $8.0M | $200.0K |
| Free cash flow | -$31.0M | -$32.8M | -$21.1M | -$48.8M |
| Capital expenditures | $20.0K | $0 | $0 | $13.0K |
| Share-based compensation | $7.6M | $7.4M | $4.9M | $4.8M |
| Deferred income taxes | — | $0 | $0 | $0 |
| Change in accounts payable | -$1.4M | $146.0K | -$1.3M | $617.0K |
Source: SEC EDGAR XBRL filings (10-Q/10-K), as originally tagged by the company. Quarterly cash flow is reconstructed by de-cumulating fiscal-year-to-date figures (how cash flow is tagged in 10-Qs); other quarterly lines are reported directly.
Institutional holders
SEC Form 13F filers holding MREO as of the latest reported quarter. 13F only covers investment managers with $100M+ in assets — this is not a complete ownership picture, and does not include insiders (see Recent SEC filings below) or non-13F-eligible holders.
Institutional ownership is not available for this symbol right now.
Insider activity
Directors, officers, and 10%+ owners' reported transactions from SEC Form 4. A filing reports a transaction; it does not by itself explain why it happened.
Insider activity is not available for this symbol right now.
Recent SEC filings
Official company reports and insider transaction filings. Form 4 reports a transaction; it does not by itself explain why it happened.
Source: SEC EDGAR submissions · updated 2026-10-22 06:15 UTC
| Filed | Form | Report period | Official filing |
|---|---|---|---|
| 2026-08-19 | 8-K | 2026-08-18 | View on SEC.gov → |
| 2026-08-11 | 10-Q | 2026-06-30 | View on SEC.gov → |
| 2026-08-11 | 8-K | 2026-08-11 | View on SEC.gov → |
| 2026-08-11 | 8-K | 2026-08-11 | View on SEC.gov → |
| 2026-05-14 | 8-K | 2026-05-14 | View on SEC.gov → |
| 2026-05-12 | 10-Q | 2026-03-31 | View on SEC.gov → |
| 2026-05-12 | 8-K | 2026-05-12 | View on SEC.gov → |
| 2026-03-27 | 8-K | 2026-03-26 | View on SEC.gov → |
| 2026-03-19 | 10-K | 2025-12-31 | View on SEC.gov → |
| 2026-03-19 | 8-K | 2026-03-19 | View on SEC.gov → |
| 2026-02-27 | 4 | 2026-02-26 | View on SEC.gov → |
| 2026-02-27 | 4 | 2026-02-26 | View on SEC.gov → |
Recent news
Headlines about MREO (Mereo BioPharma Group plc American Depositary Shares). Links open the publisher — we don’t host full articles.
-
Mereo BioPharma Group GAAP EPS of -$0.01 in-line
Seeking Alpha · 2026-08-11 -
Mereo BioPharma Reports Second Quarter 2026 Financial Results and Provides Corporate Highlights
Yahoo Finance · 2026-08-11 -
Mereo BioPharma and Sentynl Therapeutics Announce Option and License Agreement for alvelestat in Alpha-1 Antitrypsin Deficiency-Associated Lung Disease (AATD-LD)
Yahoo Finance · 2026-08-11 -
Sentynl Therapeutics and Mereo BioPharma Announce Option and License Agreement for alvelestat in Alpha-1 Antitrypsin Deficiency-Associated Lung Disease (AATD-LD)
Yahoo Finance · 2026-08-11 -
European Equities Traded in the US as American Depositary Receipts Surge in Monday Trading
Yahoo Finance · 2026-06-15 -
European Equities Traded in the US as American Depositary Receipts Rise in Tuesday Trading
Yahoo Finance · 2026-06-02 -
Mereo BioPharma Reports First Quarter 2026 Financial Results and Provides Corporate Updates
Yahoo Finance · 2026-05-12 -
We're Hopeful That Mereo BioPharma Group (NASDAQ:MREO) Will Use Its Cash Wisely
Yahoo Finance · 2026-04-07
No headlines in this category right now — try “All”.